August 2012
-
Turing Pharmaceuticals, which is the subject of several investigations into its pricing strategies, has said that it plans to begin a Phase 1 trial of its TUR-002 intranasal ketamine in the first quarter of 2016.… Read more . . .
-
Consort Medical has announced that it has created a single source supply chain for OINDPs by combining the services of device company Bespak with CDMO Aesica, which Consort acquired in September 2014. Together, the companies… Read more . . .
-
Discovery Laboratories has announced additional data from its Phase 2a trials of Aerosurf aerosolized surfactant for the treatment of respiratory distress syndrome (RDS) in premature infants 29 to 34 week gestational age. that are receiving… Read more . . .
-
Swedish DPI specialist Iconovo has won the 2015 Lund University Innovation System Innovation Prize, which comes with a SEK 150,000 award, the Lund Life Science Incubator has announced. Iconovo’s winning project, titled, “ICOone for inhaled… Read more . . .
-
The 2015 Annual meeting of the American Association of Pharmaceutical Scientists took place October 25-29 at the Orange County Convention Center in Orlando, FL. Attendance numbers for the meeting were not released, but the exposition… Read more . . .
-
Insys Therapeutics has announced the resignation of President and CEO Michael L. Babich and the appointment of John N. Kapoor to those positions, effective November 4, 2015. The company also named Daniel Brennan as Executive… Read more . . .
-
Discovery Laboratories has provided an update on its clinical development program for Aerosurf aerosolized KL4 surfactant for the treatment of respiratory distress syndrome (RDS) in premature infants. In March 2015, the company announced that it… Read more . . .
-
Acerus (formerly Trimel) has announced that it will pursue development of its Tefina nasal testosterone for the treatment of hypoactive sexual desire disorder (HSDD) instead of for female orgasmic disorder (FOD). In May 2014, the… Read more . . .
-
Alexza Pharmaceuticals has announced that it plans to reacquire US rights for Adasuve loxapine inhalation powder from Teva Pharmaceuticals USA by January 1, 2016. According to the company, “Alexza and Teva are working on a… Read more . . .
-
Novartis has announced FDA approval for the Seebri Neohaler glycopyrrolate DPI and the Utibron Neohaler indacaterol/glycopyrrolate DPI for the treatment of COPD. According to the company, both inhalers should be available in the first quarter… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland